{"id":17595,"date":"2022-06-13T19:47:18","date_gmt":"2022-06-13T14:17:18","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=17595"},"modified":"2023-08-23T17:21:58","modified_gmt":"2023-08-23T11:51:58","slug":"pulmonary-arterial-hypertension-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment","title":{"rendered":"New Clinical Developments in the Pulmonary Arterial Hypertension Treatment Domain"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a00ab503bcb3\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a00ab503bcb3\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment\/#Pulmonary_Arterial_Hypertension_Epidemiological_Facts_and_Figures\" >Pulmonary Arterial Hypertension Epidemiological Facts and Figures<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment\/#Pulmonary_Arterial_Hypertension_Market_Insight\" >Pulmonary Arterial Hypertension Market Insight<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment\/#Pulmonary_Arterial_Hypertension_Treatment_Scenario\" >Pulmonary Arterial Hypertension Treatment Scenario<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment\/#Novel_Potential_Drugs_in_Pulmonary_Arterial_Hypertension_Pipeline\" >Novel Potential Drugs in Pulmonary Arterial Hypertension Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment\/#Road_Ahead_in_Pulmonary_Arterial_Hypertension_Treatment_Domain\" >Road Ahead in Pulmonary Arterial Hypertension Treatment Domain<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment\/#FAQs\" >FAQs<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Pulmonary arterial hypertension is a progressive disease of the lung vascular system, primarily affecting the small pulmonary arterioles. Pulmonary arterial hypertension is defined as mean pulmonary artery pressure greater than 25 mm Hg measured during right heart catheterization. The term Pulmonary arterial hypertension describes a subset of patients who also have the presence of pre-capillary hypertension, including an end-expiratory pulmonary artery wedge pressure (less than 15 mm Hg) and a pulmonary vascular resistance greater than 3 Woods units. At present, there is no permanent cure for Pulmonary arterial hypertension. But several new potential developments in the Pulmonary arterial hypertension treatment landscape can reduce the symptoms and also aid in the management of the condition. When Pulmonary arterial hypertension cause is identified and treated early, it may be still possible to prevent permanent damage to the pulmonary arteries which are blood vessels responsible for the supply to the lungs.<\/p>\n\n\n\n<p>Cardinal <a href=\"https:\/\/www.delveinsight.com\/blog\/outbreak-of-companies-challenging-new-pathways-for-treatment-of-pulmonary-arterial-hypertension\">pulmonary arterial hypertension symptoms<\/a> include progressive exercise dyspnea, often accompanied by fatigue and exhaustion. Because of the fact, that Pulmonary arterial hypertension signs and symptoms are unspecific, there is often a delay of many months or even years between the onset of symptoms and diagnosis. With pulmonary arterial hypertension progression, it is observed that the symptoms become worse and new symptoms occur, e.g., <a href=\"https:\/\/www.delveinsight.com\/report-store\/dyspnea-market\">dyspnea<\/a> on bending down (bendopnea) and <a href=\"https:\/\/www.delveinsight.com\/report-store\/syncope-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\">syncope<\/a>, the latter particularly during or immediately after physical exertion. Precise pulmonary arterial hypertension classification and detection are considered to be the essential goals of diagnosis. With physical examination, the basic Pulmonary arterial hypertension diagnosis in every case of uncertain or progressive exercise dyspnea should include <a href=\"https:\/\/www.delveinsight.com\/blog\/tag\/ecg-monitoring-equipment\">ECG tests<\/a> and tests involving the determination of brain natriuretic peptide (BNP) or the N-terminal fragment of its precursor (NT-proBNP).<\/p>\n\n\n\n<p>Pulmonary arterial hypertension has been divided into three subgroups &#8211;<strong> idiopathic pulmonary arterial hypertension, heritable pulmonary arterial hypertension,<\/strong> and <strong>arterial pulmonary hypertension related to risk factors or associated conditions. <\/strong>Most commonly found among these is idiopathic pulmonary arterial hypertension and is characterized by increased vascular resistance and blood vessel narrowing within the pulmonary vasculature. Restricted flow through pulmonary arteries, as found in PAH, is thought to have molecular and genetic causes which lead to hypertrophy of smooth muscle, endothelial cells, and adventitia.<\/p>\n\n\n\n<p>Pulmonary arterial hypertension treatment has progressed significantly over the past few decades in both its complexity and efficacy. The therapy aims to achieve a low-risk status (maintaining WHO-FC II if possible) to preserve patient function, and quality of life and minimize pulmonary arterial hypertension mortality rate. Pulmonary arterial hypertension management involves a stepwise pragmatic approach from general supportive treatment up to targeted pharmacological interventions.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-cb4dde1a\"><span class=\"ez-toc-section\" id=\"Pulmonary_Arterial_Hypertension_Epidemiological_Facts_and_Figures\"><\/span><strong>Pulmonary Arterial Hypertension <\/strong><strong>Epidemiological Facts and Figures<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pulmonary arterial hypertension is a rare and progressive disorder as it gets worse with time. Usually pulmonary arterial hypertension cause is unknown, but some of the underlying suspected causes include high blood pressure, connective tissue disease, coronary artery disease, high blood pressure, and liver disease (cirrhosis). The chronic and incurable disease doesn\u2019t occur much frequently but is most common in women between the ages of 30-60. According to DelveInsight&#8217;s analysis, in the year 2021, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-epidemiology-forecast\">total prevalence of pulmonary arterial hypertension<\/a> was <strong>69,605 cases<\/strong> in the<strong> 7MM<\/strong> which will increase by 2032. The prevalence of pulmonary arterial hypertension varies widely in different geographical locations, depending upon the influence of cultures on dietary habits.<\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-cecf9ec0-f0e8-4e58-85e0-91d7fffc49ac\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 509 400\" width=\"509\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.1.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-7iqno7t-715-\"><rect fill=\"none\" height=\"271\" width=\"424\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-7iqno7t-721-\"><rect fill=\"none\" height=\"271\" width=\"424\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-7iqno7t-722-\"><rect fill=\"none\" height=\"271\" width=\"424\" x=\"75\" y=\"92\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"509\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"271\" width=\"424\" x=\"75\" y=\"92\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 159.5 92 L 159.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 244.5 92 L 244.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 328.5 92 L 328.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 413.5 92 L 413.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 498.5 92 L 498.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 74.5 92 L 74.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 75 363.5 L 499 363.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 295.5 L 499 295.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 228.5 L 499 228.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 160.5 L 499 160.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 75 91.5 L 499 91.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"271\" width=\"424\" x=\"75\" y=\"92\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-axis-line\" d=\"M 75 363.5 L 499 363.5\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><text class=\"highcharts-axis-title\" data-z-index=\"7\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0) rotate(270 26.488866806030273 227.5)\" x=\"26.488866806030273\" y=\"227.5\">Number of Cases<\/text><path class=\"highcharts-axis-line\" d=\"M 75 92 L 75 363\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" class=\"highcharts-series highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"url(#highcharts-7iqno7t-721-)\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(75,92) scale(1 1)\"><rect aria-label=\"7MM, 69,605. Column 2.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"236\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"41\" x=\"21.5\" y=\"35.5\"><\/rect><rect aria-label=\"US, 53,951. Column 2.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"183\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"41\" x=\"106.5\" y=\"88.5\"><\/rect><rect aria-label=\"France, 3,396. Column 2.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"12\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"41\" x=\"191.5\" y=\"259.5\"><\/rect><rect aria-label=\"Spain, 1,503. Column 2.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"5\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"41\" x=\"275.5\" y=\"266.5\"><\/rect><rect aria-label=\"Japan, 1,947. Column 2.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"7\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"41\" x=\"360.5\" y=\"264.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(75,92) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"255\" y=\"24\">Pulmonary Arterial Hypertension Epidemiology<tspan dy=\"21\" x=\"255\">\u200b<\/tspan>Insights<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"255\" y=\"73\">Total Prevalent Population of Pulmonary Arterial Hypertension<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-column-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(75,92) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(17,12)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">69 605<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>69 605<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(102,65)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">53 951<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>53 951<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(191,236)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">3 396<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>3 396<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(275,243)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">1 503<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>1 503<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(360,241)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">1 947<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>1 947<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"117.4\" y=\"382\">7MM<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"202.2\" y=\"382\">US<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"287\" y=\"382\">France<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"371.8\" y=\"382\">Spain<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"456.6\" y=\"382\">Japan<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"367\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"299\">20k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"232\">40k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"164\">60k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"60\" y=\"96\">80k<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Pulmonary Arterial Hypertension Epidemiology Forecast - 2030\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"499\" y=\"395\">Pulmonary Arterial Hypertension Epidemiology Forecast &#8211; 2030<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-7iqno7t-722-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Pulmonary Arterial Hypertension Epidemiology Insights\"},\"subtitle\":{\"text\":\"Total Prevalent Population of Pulmonary Arterial Hypertension\"},\"exporting\":{},\"chart\":{\"type\":\"column\",\"polar\":false},\"plotOptions\":{\"series\":{\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"series\":[{\"name\":\"Column 2\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Column 2\\\"\\n\\\"7MM\\\";69605\\n\\\"US\\\";53951\\n\\\"France \\\";3396\\n\\\"Spain\\\";1503\\n\\\"Japan\\\";1947\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{\"text\":\"Number of Cases\"}}],\"legend\":{\"enabled\":false},\"credits\":{\"text\":\"Pulmonary Arterial Hypertension Epidemiology Forecast - 2030\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-epidemiology-forecast-insight\"}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-cecf9ec0-f0e8-4e58-85e0-91d7fffc49ac\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<p>Also, as per DelveInsight\u2019s analysis, the total prevalence of pulmonary arterial hypertension in the <strong>US <\/strong>was calculated to be <strong>53,951<\/strong><strong> cases<\/strong> in the year 2021. Among the EU5 countries, <strong>France <\/strong>has the highest prevalence of pulmonary arterial hypertension cases which was<strong> 3,396 <\/strong>cases in 2021. Whereas, on the other hand, <strong>Spain <\/strong>has the lowest prevalence of pulmonary arterial hypertension among the 7MM, with <strong>1,503 cases <\/strong>in 2021. In addition, <strong>Japan <\/strong>had a total of <strong>1,947 <\/strong>pulmonary arterial hypertension prevalent cases. <a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-epidemiology-forecast\">Pulmonary arterial hypertension epidemiological segmentation<\/a> can be done on the basis of total prevalent cases of pulmonary arterial hypertension, diagnosed cases of pulmonary arterial hypertension, gender-specific cases of pulmonary arterial hypertension, and subtype-specific cases of pulmonary arterial hypertension.<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-5f2ddeb3\"><span class=\"ez-toc-section\" id=\"Pulmonary_Arterial_Hypertension_Market_Insight\"><\/span><strong>Pulmonary Arterial Hypertension Market Insight<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The overall dynamics of the Pulmonary arterial hypertension market is anticipated to change in the coming years owing to the expected launch of <a href=\"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-therapies\">potential novel and emerging therapies<\/a> backed by payer willingness to reimburse, providing affordable coverage to a large addressable population. In addition to that, the increasing incident cases, rising research on&nbsp; pulmonary arterial hypertension treatment, and increasing expenditure regarding the disease are factors responsible for the growth of the Pulmonary Arterial Hypertension market size.<\/p>\n\n\n\n<div contenteditable=\"false\"><div id=\"highcharts-b4a90ad7-9fb8-4a73-8771-547430642b1e\"><svg aria-hidden=\"false\" aria-label=\"Interactive chart\" class=\"highcharts-root\" height=\"400\" style=\"font-family: &quot;Lucida Grande&quot;, &quot;Lucida Sans Unicode&quot;, Arial, Helvetica, sans-serif; font-size: 12px;\" version=\"1.1\" viewBox=\"0 0 509 400\" width=\"509\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\"><desc aria-hidden=\"true\">Created with Highcharts 10.1.0<\/desc><defs aria-hidden=\"true\"><clipPath id=\"highcharts-u78gdb8-507-\"><rect fill=\"none\" height=\"292\" width=\"431\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-u78gdb8-510-\"><rect fill=\"none\" height=\"292\" width=\"431\" x=\"0\" y=\"0\"><\/rect><\/clipPath><clipPath id=\"highcharts-u78gdb8-511-\"><rect fill=\"none\" height=\"292\" width=\"431\" x=\"68\" y=\"71\"><\/rect><\/clipPath><\/defs><rect aria-hidden=\"true\" class=\"highcharts-background\" fill=\"#ffffff\" height=\"400\" rx=\"0\" ry=\"0\" width=\"509\" x=\"0\" y=\"0\"><\/rect><rect aria-hidden=\"true\" class=\"highcharts-plot-background\" fill=\"none\" height=\"292\" width=\"431\" x=\"68\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-pane-group\" data-z-index=\"0\"><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-xaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 176.5 71 L 176.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><path class=\"highcharts-grid-line\" d=\"M 389.5 71 L 389.5 363\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke-dasharray=\"none\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-grid highcharts-yaxis-grid\" data-z-index=\"1\"><path class=\"highcharts-grid-line\" d=\"M 68 363.5 L 499 363.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 314.5 L 499 314.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 266.5 L 499 266.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 217.5 L 499 217.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 168.5 L 499 168.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 120.5 L 499 120.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><path class=\"highcharts-grid-line\" d=\"M 68 70.5 L 499 70.5\" data-z-index=\"1\" fill=\"none\" opacity=\"1\" stroke=\"#e6e6e6\" stroke-dasharray=\"none\" stroke-width=\"1\"><\/path><\/g><rect aria-hidden=\"true\" class=\"highcharts-plot-border\" data-z-index=\"1\" fill=\"none\" height=\"292\" width=\"431\" x=\"68\" y=\"71\"><\/rect><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-xaxis\" data-z-index=\"2\"><path class=\"highcharts-tick\" d=\"M 176.5 363 L 176.5 373\" fill=\"none\" opacity=\"1\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><path class=\"highcharts-tick\" d=\"M 389.5 363 L 389.5 373\" fill=\"none\" opacity=\"1\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><path class=\"highcharts-axis-line\" d=\"M 68 363.5 L 499 363.5\" data-z-index=\"7\" fill=\"none\" stroke=\"#ccd6eb\" stroke-width=\"1\"><\/path><\/g><g aria-hidden=\"true\" class=\"highcharts-axis highcharts-yaxis\" data-z-index=\"2\"><text class=\"highcharts-axis-title\" data-z-index=\"7\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0) rotate(270 26.44443416595459 217)\" x=\"26.44443416595459\" y=\"217\">USD (in million)<\/text><path class=\"highcharts-axis-line\" d=\"M 68 71 L 68 363\" data-z-index=\"7\" fill=\"none\"><\/path><\/g><g aria-hidden=\"false\" class=\"highcharts-series-group\" data-z-index=\"3\"><g aria-hidden=\"false\" class=\"highcharts-series highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"url(#highcharts-u78gdb8-510-)\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(68,71) scale(1 1)\"><rect aria-label=\"x, 2020, 4,777. Column 2.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"232\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"103\" x=\"57.5\" y=\"60.5\"><\/rect><rect aria-label=\"x, 2022, 4,901. Column 2.\" class=\"highcharts-point highcharts-color-0\" fill=\"#7cb5ec\" height=\"239\" opacity=\"1\" role=\"img\" stroke=\"#ffffff\" stroke-width=\"1\" style=\"outline: none;\" tabindex=\"-1\" width=\"103\" x=\"270.5\" y=\"53.5\"><\/rect><\/g><g aria-hidden=\"true\" class=\"highcharts-markers highcharts-series-0 highcharts-column-series highcharts-color-0\" clip-path=\"none\" data-z-index=\"0.1\" opacity=\"1\" transform=\"translate(68,71) scale(1 1)\"><\/g><\/g><text aria-hidden=\"true\" class=\"highcharts-title\" data-z-index=\"4\" style=\"color: rgb(51, 51, 51); font-size: 18px; fill: rgb(51, 51, 51);\" text-anchor=\"middle\" x=\"255\" y=\"24\">Pulmonary Arterial Hypertension Market Insights<\/text><text aria-hidden=\"true\" class=\"highcharts-subtitle\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"middle\" x=\"255\" y=\"52\">Pulmonary Arterial Hypertension Market Size in the 7MM<\/text><text aria-hidden=\"true\" class=\"highcharts-caption\" data-z-index=\"4\" style=\"color: rgb(102, 102, 102); fill: rgb(102, 102, 102);\" text-anchor=\"start\" x=\"10\" y=\"397\"><\/text><g aria-hidden=\"true\" class=\"highcharts-data-labels highcharts-series-0 highcharts-column-series highcharts-color-0\" data-z-index=\"6\" opacity=\"1\" transform=\"translate(68,71) scale(1 1)\"><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(87,37)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\" style=\"\">4 777<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>4 777<\/text><\/g><g class=\"highcharts-label highcharts-data-label highcharts-data-label-color-0\" data-z-index=\"1\" transform=\"translate(300,30)\"><text data-z-index=\"1\" style=\"color: rgb(0, 0, 0); font-size: 11px; font-weight: bold; fill: rgb(0, 0, 0);\" x=\"5\" y=\"16\"><tspan class=\"highcharts-text-outline\" fill=\"#FFFFFF\" stroke=\"#FFFFFF\" stroke-linejoin=\"round\" stroke-width=\"2px\">4 901<tspan x=\"5\" y=\"16\">\u200b<\/tspan><\/tspan>4 901<\/text><\/g><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-xaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"176.81683168317\" y=\"382\">2020<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"middle\" transform=\"translate(0,0)\" x=\"390.18316831683\" y=\"382\">2022<\/text><\/g><g aria-hidden=\"true\" class=\"highcharts-axis-labels highcharts-yaxis-labels\" data-z-index=\"7\"><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"367\">0<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"318\">1k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"270\">2k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"221\">3k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"172\">4k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"124\">5k<\/text><text opacity=\"1\" style=\"color: rgb(102, 102, 102); cursor: default; font-size: 11px; fill: rgb(102, 102, 102);\" text-anchor=\"end\" transform=\"translate(0,0)\" x=\"53\" y=\"75\">6k<\/text><\/g><text aria-hidden=\"false\" aria-label=\"Chart credits: Pulmonary Arterial Hypertension Market Insights - 2032\" class=\"highcharts-credits\" data-z-index=\"8\" style=\"cursor: pointer; color: rgb(153, 153, 153); font-size: 9px; fill: rgb(153, 153, 153);\" text-anchor=\"end\" x=\"499\" y=\"395\">Pulmonary Arterial Hypertension Market Insights - 2032<\/text><g aria-hidden=\"true\" class=\"highcharts-control-points\" clip-path=\"url(#highcharts-u78gdb8-511-)\" data-z-index=\"99\"><\/g><\/svg><\/div><script>(function(){ var files = [\"https:\/\/code.highcharts.com\/stock\/highstock.js\",\"https:\/\/code.highcharts.com\/highcharts-more.js\",\"https:\/\/code.highcharts.com\/highcharts-3d.js\",\"https:\/\/code.highcharts.com\/modules\/data.js\",\"https:\/\/code.highcharts.com\/modules\/exporting.js\",\"https:\/\/code.highcharts.com\/modules\/funnel.js\",\"https:\/\/code.highcharts.com\/modules\/annotations.js\",\"https:\/\/code.highcharts.com\/modules\/accessibility.js\",\"https:\/\/code.highcharts.com\/modules\/solid-gauge.js\"],loaded = 0; if (typeof window[\"HighchartsEditor\"] === \"undefined\") {window.HighchartsEditor = {ondone: [cl],hasWrapped: false,hasLoaded: false};include(files[0]);} else {if (window.HighchartsEditor.hasLoaded) {cl();} else {window.HighchartsEditor.ondone.push(cl);}}function isScriptAlreadyIncluded(src){var scripts = document.getElementsByTagName(\"script\");for (var i = 0; i < scripts.length; i++) {if (scripts[i].hasAttribute(\"src\")) {if ((scripts[i].getAttribute(\"src\") || \"\").indexOf(src) >= 0 || (scripts[i].getAttribute(\"src\") === \"http:\/\/code.highcharts.com\/highcharts.js\" && src === \"https:\/\/code.highcharts.com\/stock\/highstock.js\")) {return true;}}}return false;}function check() {if (loaded === files.length) {for (var i = 0; i < window.HighchartsEditor.ondone.length; i++) {try {window.HighchartsEditor.ondone[i]();} catch(e) {console.error(e);}}window.HighchartsEditor.hasLoaded = true;}}function include(script) {function next() {++loaded;if (loaded < files.length) {include(files[loaded]);}check();}if (isScriptAlreadyIncluded(script)) {return next();}var sc=document.createElement(\"script\");sc.src = script;sc.type=\"text\/javascript\";sc.onload=function() { next(); };document.head.appendChild(sc);}function each(a, fn){if (typeof a.forEach !== \"undefined\"){a.forEach(fn);}else{for (var i = 0; i < a.length; i++){if (fn) {fn(a[i]);}}}}var inc = {},incl=[]; each(document.querySelectorAll(\"script\"), function(t) {inc[t.src.substr(0, t.src.indexOf(\"?\"))] = 1; }); function cl() {if(typeof window[\"Highcharts\"] !== \"undefined\"){var options={\"title\":{\"text\":\"Pulmonary Arterial Hypertension Market Insights\"},\"subtitle\":{\"text\":\"Pulmonary Arterial Hypertension Market Size in the 7MM\"},\"exporting\":{},\"chart\":{\"type\":\"column\",\"polar\":false},\"plotOptions\":{\"series\":{\"dataLabels\":{\"enabled\":true},\"animation\":false}},\"series\":[{\"name\":\"Column 2\",\"turboThreshold\":0}],\"data\":{\"csv\":\"\\\"Column 1\\\";\\\"Column 2\\\"\\n2020;4777\\n2022;4901\",\"googleSpreadsheetKey\":false,\"googleSpreadsheetWorksheet\":false},\"yAxis\":[{\"title\":{\"text\":\"USD (in million)\"}}],\"legend\":{\"enabled\":false},\"credits\":{\"text\":\"Pulmonary Arterial Hypertension Market Insights - 2032\",\"href\":\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pah-market\"}};\/*\/\/ Sample of extending options:Highcharts.merge(true, options, {    chart: {        backgroundColor: \"#bada55\"    },    plotOptions: {        series: {            cursor: \"pointer\",            events: {                click: function(event) {                    alert(this.name + \" clicked\\n\" +                          \"Alt: \" + event.altKey + \"\\n\" +                          \"Control: \" + event.ctrlKey + \"\\n\" +                          \"Shift: \" + event.shiftKey + \"\\n\");                }            }        }    }});*\/new Highcharts.Chart(\"highcharts-b4a90ad7-9fb8-4a73-8771-547430642b1e\", options);}}})();<\/script><\/div><p>&nbsp;<\/p>\n\n\n\n<p>As per DelveInsight's estimates, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-market\">Pulmonary arterial hypertension market size<\/a> was found to be<strong> USD 4,777 million<\/strong> in the <strong>7MM <\/strong>in the year <strong>2020<\/strong>. Additionally, it is anticipated that it will accumulate almost<strong> USD 4,901 million<\/strong> in the year <strong>2022 <\/strong>in the seven major markets. Following a similar trend, the Pulmonary Arterial Hypertension market size is anticipated to increase at a substantial growth rate in the coming years.<\/p>\n\n\n\n<p>Many key pharmaceuticals that are proactively involved in producing <a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pipeline-insight\">pulmonary arterial hypertension medications<\/a> in the coming years include names such as<strong> Pfizer, Eli Lilly and Company, United Therapeutics Corporation, Gilead Sciences, GlaxoSmithKline, ICOS Corporation, Actelion Pharmaceuticals, Nippon Shinyaku, United Therapeutics Corporation, Bayer Group, Co Therix, PhaseBio Pharmaceuticals, Liquida Technologies, Inc., Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, Gossamer Bio Inc., Merck Sharp &amp; Dohme Corp, Insmed Incorporated, Pharmaosa Biopharma Inc. <\/strong>whose key Pulmonary arterial hypertension treatment therapies are expected to be launched in the coming years and can also serve as a major booster for pulmonary arterial hypertension treatment market.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13194849\/Leading-Companies-in-the-Pulmonary-Arterial-Hypertension-Market-1024x300.png\" alt=\"Leading Players in the Pulmonary Arterial Hypertension Market\" class=\"wp-image-17613\" width=\"1024\" height=\"300\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13194849\/Leading-Companies-in-the-Pulmonary-Arterial-Hypertension-Market-1024x300.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13194849\/Leading-Companies-in-the-Pulmonary-Arterial-Hypertension-Market-300x88.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13194849\/Leading-Companies-in-the-Pulmonary-Arterial-Hypertension-Market-150x44.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13194849\/Leading-Companies-in-the-Pulmonary-Arterial-Hypertension-Market-768x225.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13194849\/Leading-Companies-in-the-Pulmonary-Arterial-Hypertension-Market.png 1035w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><figcaption class=\"wp-element-caption\"><strong>Leading Players in the Pulmonary Arterial Hypertension Market<\/strong><\/figcaption><\/figure>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-82c94353\"><span class=\"ez-toc-section\" id=\"Pulmonary_Arterial_Hypertension_Treatment_Scenario\"><\/span><strong>Pulmonary Arterial Hypertension Treatment Scenario<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The diversity in the approaches regarding pulmonary arterial hypertension treatment is due to the multiple etiologies including idiopathic pulmonary hypertension, drug-induced pulmonary arterial hypertension treatment, connective tissue disorder, and congenital heart disease. The current&nbsp; pulmonary arterial hypertension treatment landscape ranges from the use of vasodilators to endothelial receptor antagonists. General measures, supportive therapy, pharmacological treatment, and surgical treatment are also used for pulmonary arterial hypertension treatment.<\/p>\n\n\n\n<p><strong>Revatio is a phosphodiesterase-5 (PDE-5) inhibitor <\/strong>indicated for pulmonary arterial hypertension treatment in adults to improve exercise ability and delay clinical worsening. Revatio is available as tablets and oral suspension for oral use and injection for intravenous use. <strong>Selexipag (Uptravi)<\/strong> is an orally active, first-in-class, selective prostacyclin IP receptor agonist. Selexipag was FDA approved for the long-term pulmonary arterial hypertension treatment in adult patients. <strong>Iloprost (Ventavis)<\/strong> is a second-generation structural analog of prostacyclin PGI2 that dilates systemic and pulmonary arterial vascular beds and aids in pulmonary arterial hypertension treatment. <strong>Ambrisentan (Letairis)<\/strong> is an orally active selective type A endothelin receptor antagonist indicated for treating pulmonary arterial hypertension.<\/p>\n\n\n\n<p>The therapeutic intervention is classified into <strong>Calcium Channel Blockers (CCBs), Endothelin Receptor Antagonists (ERAs), and Phosphodiesterase-5 (PDE-5) inhibitors<\/strong> are used as the pharmacological Pulmonary arterial hypertension treatment.<\/p>\n\n\n\n<p><strong><em>Read More About - <a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-market\" class=\"ek-link\">Pulmonary Arterial Hypertension Market Outlook<\/a><\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-fe95a32f\" id=\"h-novel-potential-drugs-in-pulmonary-arterial-hypertension-pipeline\"><span class=\"ez-toc-section\" id=\"Novel_Potential_Drugs_in_Pulmonary_Arterial_Hypertension_Pipeline\"><\/span><strong>Novel Potential Drugs in <\/strong><strong>Pulmonary Arterial Hypertension<\/strong><strong> Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pulmonary arterial hypertension treatment is a rapidly changing landscape, with arguably, the most significant advancement in recent years. The market is anticipated to evolve in the coming years owing to the expected launch of <a href=\"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-therapies\">emerging Pulmonary arterial hypertension therapies<\/a> such as Sotatercept (Acceleron Pharma Inc.), Ralinepag (United Therapeutics), Rodatristat ethyl (Altavant Sciences), RT234 (Respira Therapeutics) and many more by key players in the pulmonary arterial hypertension treatment regime.&nbsp;<\/p>\n\n\n\n<p>Also, the launch of various multiple-stage pulmonary arterial hypertension pipeline products will significantly revolutionize the <a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-market\">Pulmonary Arterial Hypertension market<\/a> dynamics shortly. Some of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-pipeline-insight\">pulmonary arterial hypertension pipeline drugs<\/a> under different phases of development in several clinical trials include -<\/p>\n\n\n\n<p><strong>Sotatercept <\/strong>is an investigational agent being designed by <strong>Acceleron Pharma Inc. <\/strong>to be a selective ligand trap for members of the TGF-beta superfamily to rebalance BMPR-II signaling, which is a key molecular driver of Pulmonary arterial hypertension. Recent topline analysis of the <strong>PULSAR Phase II trial <\/strong>of sotatercept in patients with pulmonary arterial hypertension revealed the trial met the primary as well as key and other secondary endpoints, with adverse events consistent with previously published data on sotatercept in other diseases. Sotatercept received Orphan Drug designation from the US Food and Drug Administration (FDA) for Pulmonary arterial hypertension treatment in the year 2019.<\/p>\n\n\n\n<p><strong>Ralinepag <\/strong>is currently under investigation by <strong>United Therapeutics.<\/strong> It is a next-generation, orally available, non-prostanoid, selective, and potent IP agonist which has been studied in human pulmonary tissues for the treatment of pulmonary arterial hypertension. In vitro studies indicate that Ralinepag has high binding affinity and selectivity at the human IP receptor.<\/p>\n\n\n\n<p><strong>Rodatristat Ethyl<\/strong> is <strong>Altavant\u2019s <\/strong>lead candidate, is a prodrug of a tryptophan hydroxylase (TPH) inhibitor designed to block peripheral serotonin production. Rodatristat, delivered as a prodrug (rodatristat ethyl), is an orally bioavailable direct and reversible TPH inhibitor for pulmonary arterial hypertension treatment.<\/p>\n\n\n\n<p><strong>AV-101<\/strong> is under examination by <strong>Aerovate Therapeutics<\/strong>. It is a novel dry powder formulation of the FDA-approved therapy Imatinib. Dosed specifically for pulmonary arterial hypertension treatment, designed specifically for delivery by a dry powder inhaler, directly into the lungs to halt the proliferation of cells, improving heart function and everyday health.<\/p>\n\n\n\n<p><strong>RT234<\/strong> is <strong>Respira\u2019s<\/strong> lead drug-device product candidate for pulmonary arterial hypertension treatment. It is a first-in-class inhaled therapy intended for as-needed (PRN) use to improve exercise tolerance and provide acute relief from breathlessness and fatigue, the most commonly reported symptoms in pulmonary arterial hypertension patients.<\/p>\n\n\n\n<p><strong>Zamicastat <\/strong>is a dopamine \u03b2-hydroxylase (DBH) inhibitor under investigation by <strong>Bial <\/strong>and can cross the blood-brain barrier (BBB) to cause central as well as peripheral effects. Dopamine \u03b2 hydroxylase (DBH) \u2013 a key player in the catecholamine biosynthetic pathway \u2013 may provide a therapeutic opportunity for pulmonary arterial hypertension treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-3d6e985e\"><span class=\"ez-toc-section\" id=\"Road_Ahead_in_Pulmonary_Arterial_Hypertension_Treatment_Domain\"><\/span><strong>Road Ahead in Pulmonary Arterial Hypertension Treatment Domain<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Recent developments in the pharmacotherapy for pulmonary arterial hypertension treatment has led to novel FDA approvals of agents such as ERAs, nitric oxide modulators, and prostacyclin therapies that target the underlying pulmonary arterial hypertension pathophysiology, these therapeutic options have increased drastically over the last decades. The rise of pharmacological interventions targeting the prostacyclin, endothelin, and NO pathways has significantly improved the results.&nbsp;<\/p>\n\n\n\n<p>Even after much research and clinical development, pulmonary arterial hypertension remains a life-limiting illness with no prospect of cure. Despite success in preclinical models. by utilizing a number of potential novel approaches targeting cellular GPCRs, metabolism, growth factor receptors, ion channels, transcription factors, and inflammation, fruitful transfer to human disease with constructive results in the clinical trials were observed to be limited.&nbsp;<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/pulmonary-arterial-hypertension-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13174051\/Pulmonary-Arterial-Hypertension-report-1024x256.png\" alt=\"Pulmonary Arterial Hypertension report\" class=\"wp-image-17603\" width=\"1024\" height=\"256\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13174051\/Pulmonary-Arterial-Hypertension-report-1024x256.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13174051\/Pulmonary-Arterial-Hypertension-report-300x75.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13174051\/Pulmonary-Arterial-Hypertension-report-150x38.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13174051\/Pulmonary-Arterial-Hypertension-report-768x192.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13174051\/Pulmonary-Arterial-Hypertension-report-1536x384.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13174051\/Pulmonary-Arterial-Hypertension-report-1568x392.png 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13174051\/Pulmonary-Arterial-Hypertension-report.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-704ba596\"><span class=\"ez-toc-section\" id=\"FAQs\"><\/span><strong>FAQs<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"schema-faq wp-block-yoast-faq-block\"><div class=\"schema-faq-section\" id=\"faq-question-1655121899930\"><strong class=\"schema-faq-question\">How to diagnose Pulmonary Arterial Hypertension?<\/strong> <p class=\"schema-faq-answer\">Pulmonary Arterial Hypertension diagnosis includes several blood tests, chest X-ray, electrocardiogram, echocardiogram, right heart catheterization, and several other tests.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1655121909176\"><strong class=\"schema-faq-question\">Is Pulmonary Arterial Hypertension terminal?<\/strong> <p class=\"schema-faq-answer\">Pulmonary hypertension is considered a life-threatening condition that can worsen over time, but proper detection and treatments can help in symptomatic relief, to live better with the disease.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1655121918033\"><strong class=\"schema-faq-question\">Can Pulmonary Arterial Hypertension be cured?<\/strong> <p class=\"schema-faq-answer\">No, Pulmonary Arterial Hypertension can not be completely cured. But treatment can help in the reduction of symptoms.<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1655121928812\"><strong class=\"schema-faq-question\">What causes Pulmonary Arterial Hypertension?<\/strong> <p class=\"schema-faq-answer\">Pulmonary arterial hypertension causes include high blood pressure, connective tissue disease, coronary artery disease, high blood pressure, and liver disease (cirrhosis).<\/p> <\/div> <div class=\"schema-faq-section\" id=\"faq-question-1655121933783\"><strong class=\"schema-faq-question\">What all companies are working in the Pulmonary Arterial Hypertension market?<\/strong> <p class=\"schema-faq-answer\">Key pharmaceuticals involved in producing pulmonary arterial hypertension medications in the coming years include names such as Pfizer, Eli Lilly and Company, United Therapeutics Corporation, Gilead Sciences, GlaxoSmithKline, ICOS Corporation, Actelion Pharmaceuticals, Nippon Shinyaku, United Therapeutics Corporation, Bayer Group, Co Therix, PhaseBio Pharmaceuticals, Liquida Technologies, Inc., Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, Gossamer Bio Inc., Merck Sharp &amp; Dohme Corp, Insmed Incorporated, Pharmaosa Biopharma Inc. whose key Pulmonary arterial hypertension treatment therapies are expected to be launched in the coming years.<\/p> <\/div> <\/div>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pulmonary arterial hypertension is a progressive disease of the lung vascular system, primarily affecting the small pulmonary arterioles. Pulmonary arterial hypertension is defined as mean pulmonary artery pressure greater than 25 mm Hg measured during right heart catheterization. The term Pulmonary arterial hypertension describes a subset of patients who also have the presence of pre-capillary [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":17602,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":9,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[19412,2209,4044,499,4067,4066,19413],"industry":[17225],"therapeutic_areas":[17242,17234,17243],"class_list":["post-17595","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-dyspnea","tag-electroencephalogram-eeg","tag-hypertension","tag-pulmonary-arterial-hypertension","tag-pulmonary-arterial-hypertension-market","tag-pulmonary-arterial-hypertension-treatment","tag-syncope","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-rare-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>New Developments in Pulmonary arterial hypertension treatment Pipeline<\/title>\n<meta name=\"description\" content=\"Pulmonary arterial hypertension treatment market to grow due to launch of novel therapies, large addressable market, key companies in therapy\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Developments in Pulmonary arterial hypertension treatment Pipeline\" \/>\n<meta property=\"og:description\" content=\"Pulmonary arterial hypertension treatment market to grow due to launch of novel therapies, large addressable market, key companies in therapy\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-13T14:17:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-23T11:51:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13173845\/pulmonary-arterial-hypertension.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"New Developments in Pulmonary arterial hypertension treatment Pipeline","description":"Pulmonary arterial hypertension treatment market to grow due to launch of novel therapies, large addressable market, key companies in therapy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment","og_locale":"en_US","og_type":"article","og_title":"New Developments in Pulmonary arterial hypertension treatment Pipeline","og_description":"Pulmonary arterial hypertension treatment market to grow due to launch of novel therapies, large addressable market, key companies in therapy","og_url":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-06-13T14:17:18+00:00","article_modified_time":"2023-08-23T11:51:58+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13173845\/pulmonary-arterial-hypertension.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment","url":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment","name":"New Developments in Pulmonary arterial hypertension treatment Pipeline","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13173845\/pulmonary-arterial-hypertension.png","datePublished":"2022-06-13T14:17:18+00:00","dateModified":"2023-08-23T11:51:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Pulmonary arterial hypertension treatment market to grow due to launch of novel therapies, large addressable market, key companies in therapy","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121899930"},{"@id":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121909176"},{"@id":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121918033"},{"@id":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121928812"},{"@id":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121933783"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13173845\/pulmonary-arterial-hypertension.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13173845\/pulmonary-arterial-hypertension.png","width":772,"height":482,"caption":"pulmonary arterial hypertension"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121899930","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121899930","name":"How to diagnose Pulmonary Arterial Hypertension?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Pulmonary Arterial Hypertension diagnosis includes several blood tests, chest X-ray, electrocardiogram, echocardiogram, right heart catheterization, and several other tests.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121909176","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121909176","name":"Is Pulmonary Arterial Hypertension terminal?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Pulmonary hypertension is considered a life-threatening condition that can worsen over time, but proper detection and treatments can help in symptomatic relief, to live better with the disease.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121918033","position":3,"url":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121918033","name":"Can Pulmonary Arterial Hypertension be cured?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"No, Pulmonary Arterial Hypertension can not be completely cured. But treatment can help in the reduction of symptoms.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121928812","position":4,"url":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121928812","name":"What causes Pulmonary Arterial Hypertension?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Pulmonary arterial hypertension causes include high blood pressure, connective tissue disease, coronary artery disease, high blood pressure, and liver disease (cirrhosis).","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121933783","position":5,"url":"https:\/\/www.delveinsight.com\/blog\/pulmonary-arterial-hypertension-treatment#faq-question-1655121933783","name":"What all companies are working in the Pulmonary Arterial Hypertension market?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Key pharmaceuticals involved in producing pulmonary arterial hypertension medications in the coming years include names such as Pfizer, Eli Lilly and Company, United Therapeutics Corporation, Gilead Sciences, GlaxoSmithKline, ICOS Corporation, Actelion Pharmaceuticals, Nippon Shinyaku, United Therapeutics Corporation, Bayer Group, Co Therix, PhaseBio Pharmaceuticals, Liquida Technologies, Inc., Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, Gossamer Bio Inc., Merck Sharp &amp; Dohme Corp, Insmed Incorporated, Pharmaosa Biopharma Inc. whose key Pulmonary arterial hypertension treatment therapies are expected to be launched in the coming years.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/06\/13173845\/pulmonary-arterial-hypertension-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">dyspnea<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">electroencephalogram (EEG)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">hypertension<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pulmonary arterial hypertension<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pulmonary Arterial Hypertension market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pulmonary Arterial Hypertension treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">syncope<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">dyspnea<\/span>","<span class=\"advgb-post-tax-term\">electroencephalogram (EEG)<\/span>","<span class=\"advgb-post-tax-term\">hypertension<\/span>","<span class=\"advgb-post-tax-term\">Pulmonary arterial hypertension<\/span>","<span class=\"advgb-post-tax-term\">Pulmonary Arterial Hypertension market<\/span>","<span class=\"advgb-post-tax-term\">Pulmonary Arterial Hypertension treatment<\/span>","<span class=\"advgb-post-tax-term\">syncope<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 4 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Jun 13, 2022","modified":"Updated on Aug 23, 2023"},"absolute_dates_time":{"created":"Posted on Jun 13, 2022 7:47 pm","modified":"Updated on Aug 23, 2023 5:21 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=17595"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/17595\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/17602"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=17595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=17595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=17595"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=17595"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=17595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}